カテゴリ： GlobalData, アメリカ, 企業調査

Achillion Pharmaceuticals Inc (ACHN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Achillion Pharmaceuticals Inc (ACHN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9869
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD) and chronic obstructive pulmonary disease (COPD). Achillion is headquartered in New Haven, Connecticut, the US.

Achillion Pharmaceuticals Inc (ACHN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Achillion Pharma Enters into Licensing Agreement with Ora 11
Equity Offering 12
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc – Key Competitors 20
Achillion Pharmaceuticals Inc – Key Employees 21
Achillion Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 08, 2018: Achillion reports second quarter 2018 financial results 23
May 02, 2018: Achillion Reports First Quarter 2018 Financial Results and Management Transition 25
Feb 22, 2018: Achillion Announces Restructuring to Advance Corporate Strategy; Announces 2017 Fourth Quarter and Full Year Financial Results 27
Nov 01, 2017: Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs 29
Aug 08, 2017: Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor 30
May 04, 2017: Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs 33
Feb 23, 2017: Achillion Reports 2016 Fourth Quarter and Year-End Financial Results 35
Corporate Communications 37
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer 37
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer 38
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer 39
Sep 11, 2017: Achillion Announces Strengthening of Management Team 40
Jul 10, 2017: Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change 41
Product News 42
09/11/2017: Janssen to Discontinue Hepatitis C Development Program 42
02/26/2018: Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy 43
Product Approvals 44
Nov 06, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 44
Clinical Trials 45
Jul 10, 2018: Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D 45
Dec 20, 2017: Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D 46
Dec 18, 2017: Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study 47
Nov 14, 2017: Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G 48
Nov 01, 2017: Achillion Provides Update on ACH-4471 50
Nov 01, 2017: Achillion Provides Update on ACH-5228 52
Oct 23, 2017: Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting 53
Apr 24, 2017: Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178) 54
Apr 22, 2017: Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 55
Apr 06, 2017: Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria 56
Apr 06, 2017: New data for simeprevir will be presented at EASL’s International Liver Congress 2017 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Achillion Pharma Enters into Licensing Agreement with Ora 11
Achillion Pharma to Raise up to USD75 Million in Public Offering of Shares 12
Achillion Pharma to Raise Funds through Secondary Offering of Shares 13
Achillion Pharma Raises USD225 Million in Private Placement of Shares 14
Achillion Pharma Raises USD141.4 Million in Public Offering of Shares 16
Achillion Pharma Completes Public Offering Of Shares For US$142 Million 17
Achillion Pharma Completes Private Placement Of Shares For US$42 Million 19
Achillion Pharmaceuticals Inc, Key Competitors 20
Achillion Pharmaceuticals Inc, Key Employees 21

List of Figures
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Achillion Pharmaceuticals Inc (ACHN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Astron Corporation Ltd (ATR)：企業の財務・戦略的SWOT分析
    Astron Corporation Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • GDS Holdings Ltd (GDS)：企業の財務・戦略的SWOT分析
    GDS Holdings Ltd (GDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bacardi Limited：企業の戦略・SWOT・財務情報
    Bacardi Limited - Strategy, SWOT and Corporate Finance Report Summary Bacardi Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sumitomo Bakelite Co Ltd (4203)：企業の財務・戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Douglas Holding AG：戦略・SWOT・企業財務分析
    Douglas Holding AG - Strategy, SWOT and Corporate Finance Report Summary Douglas Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Neiman Marcus Group LTD LLC：戦略・SWOT・企業財務分析
    Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report Summary Neiman Marcus Group LTD LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Publix Super Markets Inc：企業の戦略的SWOT分析
    Publix Super Markets Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Kajima Corporation：企業の戦略・SWOT・財務情報
    Kajima Corporation - Strategy, SWOT and Corporate Finance Report Summary Kajima Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Quickstep Holdings Limited：企業の戦略・SWOT・財務情報
    Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Quickstep Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Pine Cliff Energy Ltd (PNE)：企業の財務・戦略的SWOT分析
    Summary Pine Cliff Energy Ltd (Pine Cliff) is an oil and gas company that offers exploration, production, and development of natural gas, crude oil, and natural gas liquids. The company operates through its core areas such as Edson Assets, Central Assets, and Southern Assets. It acquired Hatton prop …
  • Berkshire Hathaway Inc：戦略・SWOT・企業財務分析
    Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report Summary Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Nanobiotix SA (NANO)：企業の製品パイプライン分析
    Summary Nanobiotix SA (Nanobiotix) designs and manufactures nanomedicines for the treatment of cancer. The company is evaluating its lead product candidate NBTXR3 against soft tissue sarcoma, pancreatic, liver, rectal, prostate, head and neck cancers; Non-small cell lung cancer (NSCLC); recurrent he …
  • Valneva SE (VLA)：企業の財務・戦略的SWOT分析
    Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Johnson Electric Holdings Limited (179)：企業の財務・戦略的SWOT分析
    Johnson Electric Holdings Limited (179) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Vertex Pharmaceuticals Incorporated：企業の戦略・SWOT・財務情報
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Flexsteel Industries Inc (FLXS)：企業の財務・戦略的SWOT分析
    Flexsteel Industries Inc (FLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Australian Postal Corporation：企業の戦略的SWOT分析
    Australian Postal Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Quadrise Fuels International Plc (QFI)-石油・ガス分野：企業M&A・提携分析
    Summary Quadrise Fuels International Plc (QFI), formerly Zareba Plc, is an oil-in-water emulsified fuel developer that manufactures and markets MSAR (Multiphase Superfine Atomised Residue), an emulsion fuel as a low cost substitute for conventional heavy fuel oil (HFO) for use in power generation pl …
  • Karus Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 i …
  • The Better Drinks Co Limited：企業の戦略・SWOT・財務情報
    The Better Drinks Co Limited - Strategy, SWOT and Corporate Finance Report Summary The Better Drinks Co Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆